Colon Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Colon Cancer – Pipeline Review, H2 2016’, provides an overview of the Colon Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colon Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Colon Cancer

The report reviews pipeline therapeutics for Colon Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Colon Cancer therapeutics and enlists all their major and minor projects

The report assesses Colon Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Colon Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Colon Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Actinium Pharmaceuticals Inc

Adamed Sp z oo

Adgero Biopharmaceuticals Inc

Advanced Cancer Therapeutics

Advanced Proteome Therapeutics Corp

Advenchen Laboratories LLC

Aeglea BioTherapeutics Inc

Affimed GmbH

Agenus Inc

AGV Discovery SAS

AIMM Therapeutics BV

Almac Discovery Ltd

Ambrx Inc

Anavex Life Sciences Corp

AndroScience Corp

Aphios Corp

Aposense Ltd

Aptose Biosciences Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

BCN Biosciences LLC

Bio-Path Holdings Inc

BioCancell Ltd

Biogazelle NV

Bioncotech Therapeutics SL

Blirt SA

Boehringer Ingelheim GmbH

Can-Fite BioPharma Ltd

Celprogen Inc

Chiome Bioscience Inc

Cyclacel Pharmaceuticals Inc

CytomX Therapeutics Inc

Cytune Pharma SAS

CZ BioMed Corp

Daiichi Sankyo Company Ltd

DEKK-TEC Inc

Eli Lilly and Company

EntreChem SL

EnzymeBioSystems

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

GlycaNova Norway AS

GlycoMimetics Inc

Grunenthal GmbH

Halozyme Therapeutics Inc

Hamlet Pharma AB

Hanmi Pharmaceuticals Co Ltd

Helix BioPharma Corp

Histogen Inc

Horizon Pharma Plc

Idera Pharmaceuticals Inc

Immune Pharmaceuticals Inc

Immunome Inc

Immunomedics Inc

Immunotope Inc

Immupharma Plc

IMPACT Therapeutics Inc

Incuron LLC

Infinity Pharmaceuticals Inc

Inflection Biosciences Ltd

Innopharmax Inc

Intezyne Technologies Inc

Ironwood Pharmaceuticals Inc

Jasco Pharmaceuticals LLC

Jiangsu Kanion Pharmaceutical Co Ltd

JW Pharmaceutical Corp

Karyopharm Therapeutics Inc

Kyowa Hakko Kirin Co Ltd

Les Laboratoires Servier SAS

Lipocure Ltd

Lupin Ltd

Lymphocyte Activation Technologies SA

MabVax Therapeutics Holdings Inc

MacroGenics Inc

MaxiVAX SA

Meabco A/S

Medicenna Therapeutics Inc

Microlin Bio, Inc.

Molecular Targeting Technologies Inc

MolMed SpA

Monopar Therapeutics LLC

Multimmune GmbH

NormOxys Inc

Northwest Biotherapeutics Inc

Novartis AG

Omeros Corp

Omnitura Therapeutics Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Orega Biotech SAS

OSE Immunotherapeutics

Panacea Pharmaceuticals Inc

Patrys Ltd

PharmaCyte Biotech Inc

Pharminox Ltd

Philogen SpA

Pique Therapeutics

Plexxikon Inc

ProNAi Therapeutics Inc

Provecs Medical GmbH

Provectus Biopharmaceuticals Inc

Qu Biologics Inc

Recce Pty Ltd

Rexahn Pharmaceuticals Inc

Rgenix Inc

Sareum Holdings Plc

Savoy Pharmaceuticals Inc

Sellas Inc

Sigma-Tau SpA

Sirnaomics Inc

SOM Biotech SL

Somantix BV

Sorrento Therapeutics Inc

Sphaera Pharma Pvt Ltd

Starpharma Holdings Ltd

Sunshine Biopharma Inc

Synergys Biotherapeutics Inc

TaiRx Inc

Taiwan Liposome Company Ltd

Takis Srl

Targovax ASA

Transgene Biotek Ltd

TVAX Biomedical Inc

Tyg Oncology Ltd

TyrNovo Ltd

Vaccinogen Inc

Vault Pharma Inc

Vaxenta Biotechnologies

Vaximm AG

VG Life Sciences Inc

Yakult Honsha Co Ltd

Zensun (Shanghai) Sci & Tech Co Ltd

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Colon Cancer Overview 9

Therapeutics Development 10

Colon Cancer - Therapeutics under Development by Companies 12

Colon Cancer - Therapeutics under Investigation by Universities/Institutes 23

Colon Cancer - Pipeline Products Glance 26

Colon Cancer - Products under Development by Companies 29

Colon Cancer - Products under Investigation by Universities/Institutes 42

Colon Cancer - Companies Involved in Therapeutics Development 46

Colon Cancer - Therapeutics Assessment 179

Drug Profiles 203

Colon Cancer - Dormant Projects 660

Colon Cancer - Discontinued Products 680

Colon Cancer - Product Development Milestones 681

Appendix 692

List of Tables

List of Tables

Number of Products under Development for Colon Cancer, H2 2016 39

Number of Products under Development for Colon Cancer – Comparative Analysis, H2 2016 40

Number of Products under Development by Companies, H2 2016 41

Number of Products under Development by Companies, H2 2016 (Contd..1) 42

Number of Products under Development by Companies, H2 2016 (Contd..2) 43

Number of Products under Development by Companies, H2 2016 (Contd..3) 44

Number of Products under Development by Companies, H2 2016 (Contd..4) 45

Number of Products under Development by Companies, H2 2016 (Contd..5) 46

Number of Products under Development by Companies, H2 2016 (Contd..6) 47

Number of Products under Development by Companies, H2 2016 (Contd..7) 48

Number of Products under Development by Companies, H2 2016 (Contd..8) 49

Number of Products under Development by Companies, H2 2016 (Contd..9) 50

Number of Products under Development by Companies, H2 2016 (Contd..10) 51

Number of Products under Investigation by Universities/Institutes, H2 2016 52

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 53

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 54

Comparative Analysis by Late Stage Development, H2 2016 55

Comparative Analysis by Clinical Stage Development, H2 2016 56

Comparative Analysis by Early Stage Development, H2 2016 57

Products under Development by Companies, H2 2016 58

Products under Development by Companies, H2 2016 (Contd..1) 59

Products under Development by Companies, H2 2016 (Contd..2) 60

Products under Development by Companies, H2 2016 (Contd..3) 61

Products under Development by Companies, H2 2016 (Contd..4) 62

Products under Development by Companies, H2 2016 (Contd..5) 63

Products under Development by Companies, H2 2016 (Contd..6) 64

Products under Development by Companies, H2 2016 (Contd..7) 65

Products under Development by Companies, H2 2016 (Contd..8) 66

Products under Development by Companies, H2 2016 (Contd..9) 67

Products under Development by Companies, H2 2016 (Contd..10) 68

Products under Development by Companies, H2 2016 (Contd..11) 69

Products under Development by Companies, H2 2016 (Contd..12) 70

Products under Investigation by Universities/Institutes, H2 2016 71

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 72

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 73

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 74

Colon Cancer – Pipeline by Actinium Pharmaceuticals Inc, H2 2016 75

Colon Cancer – Pipeline by Adamed Sp z oo, H2 2016 76

Colon Cancer – Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 77

Colon Cancer – Pipeline by Advanced Cancer Therapeutics, H2 2016 78

Colon Cancer – Pipeline by Advanced Proteome Therapeutics Corp, H2 2016 79

Colon Cancer – Pipeline by Advenchen Laboratories LLC, H2 2016 80

Colon Cancer – Pipeline by Aeglea BioTherapeutics Inc, H2 2016 81

Colon Cancer – Pipeline by Affimed GmbH, H2 2016 82

Colon Cancer – Pipeline by Agenus Inc, H2 2016 83

Colon Cancer – Pipeline by AGV Discovery SAS, H2 2016 84

Colon Cancer – Pipeline by AIMM Therapeutics BV, H2 2016 85

Colon Cancer – Pipeline by Almac Discovery Ltd, H2 2016 86

Colon Cancer – Pipeline by Ambrx Inc, H2 2016 87

Colon Cancer – Pipeline by Anavex Life Sciences Corp, H2 2016 88

Colon Cancer – Pipeline by AndroScience Corp, H2 2016 89

Colon Cancer – Pipeline by Aphios Corp, H2 2016 90

Colon Cancer – Pipeline by Aposense Ltd, H2 2016 91

Colon Cancer – Pipeline by Aptose Biosciences Inc, H2 2016 92

Colon Cancer – Pipeline by AstraZeneca Plc, H2 2016 93

Colon Cancer – Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 94

Colon Cancer – Pipeline by BCN Biosciences LLC, H2 2016 95

Colon Cancer – Pipeline by Bio-Path Holdings Inc, H2 2016 96

Colon Cancer – Pipeline by BioCancell Ltd, H2 2016 97

Colon Cancer – Pipeline by Biogazelle NV, H2 2016 98

Colon Cancer – Pipeline by Bioncotech Therapeutics SL, H2 2016 99

Colon Cancer – Pipeline by Blirt SA, H2 2016 100

Colon Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 101

Colon Cancer – Pipeline by Can-Fite BioPharma Ltd, H2 2016 102

Colon Cancer – Pipeline by Celprogen Inc, H2 2016 103

Colon Cancer – Pipeline by Chiome Bioscience Inc, H2 2016 104

Colon Cancer – Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 105

Colon Cancer – Pipeline by CytomX Therapeutics Inc, H2 2016 106

Colon Cancer – Pipeline by Cytune Pharma SAS, H2 2016 107

Colon Cancer – Pipeline by CZ BioMed Corp, H2 2016 108

Colon Cancer – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 109

Colon Cancer – Pipeline by DEKK-TEC Inc, H2 2016 110

Colon Cancer – Pipeline by Eli Lilly and Company, H2 2016 111

Colon Cancer – Pipeline by EntreChem SL, H2 2016 112

Colon Cancer – Pipeline by EnzymeBioSystems, H2 2016 113

Colon Cancer – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 114

Colon Cancer – Pipeline by GlaxoSmithKline Plc, H2 2016 115

Colon Cancer – Pipeline by GlycaNova Norway AS, H2 2016 116

Colon Cancer – Pipeline by GlycoMimetics Inc, H2 2016 117

Colon Cancer – Pipeline by Grunenthal GmbH, H2 2016 118

Colon Cancer – Pipeline by Halozyme Therapeutics Inc, H2 2016 119

Colon Cancer – Pipeline by Hamlet Pharma AB, H2 2016 120

Colon Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 121

Colon Cancer – Pipeline by Helix BioPharma Corp, H2 2016 122

Colon Cancer – Pipeline by Histogen Inc, H2 2016 123

Colon Cancer – Pipeline by Horizon Pharma Plc, H2 2016 124

Colon Cancer – Pipeline by Idera Pharmaceuticals Inc, H2 2016 125

Colon Cancer – Pipeline by Immune Pharmaceuticals Inc, H2 2016 126

Colon Cancer – Pipeline by Immunome Inc, H2 2016 127

Colon Cancer – Pipeline by Immunomedics Inc, H2 2016 128

Colon Cancer – Pipeline by Immunotope Inc, H2 2016 129

Colon Cancer – Pipeline by Immupharma Plc, H2 2016 130

Colon Cancer – Pipeline by IMPACT Therapeutics Inc, H2 2016 131

Colon Cancer – Pipeline by Incuron LLC, H2 2016 132

Colon Cancer – Pipeline by Infinity Pharmaceuticals Inc, H2 2016 133

Colon Cancer – Pipeline by Inflection Biosciences Ltd, H2 2016 134

Colon Cancer – Pipeline by Innopharmax Inc, H2 2016 135

Colon Cancer – Pipeline by Intezyne Technologies Inc, H2 2016 136

Colon Cancer – Pipeline by Ironwood Pharmaceuticals Inc, H2 2016 137

Colon Cancer – Pipeline by Jasco Pharmaceuticals LLC, H2 2016 138

Colon Cancer – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2016 139

Colon Cancer – Pipeline by JW Pharmaceutical Corp, H2 2016 140

Colon Cancer – Pipeline by Karyopharm Therapeutics Inc, H2 2016 141

Colon Cancer – Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 142

Colon Cancer – Pipeline by Les Laboratoires Servier SAS, H2 2016 143

Colon Cancer – Pipeline by Lipocure Ltd, H2 2016 144

Colon Cancer – Pipeline by Lupin Ltd, H2 2016 145

Colon Cancer – Pipeline by Lymphocyte Activation Technologies SA, H2 2016 146

Colon Cancer – Pipeline by MabVax Therapeutics Holdings Inc, H2 2016 147

Colon Cancer – Pipeline by MacroGenics Inc, H2 2016 148

Colon Cancer – Pipeline by MaxiVAX SA, H2 2016 149

Colon Cancer – Pipeline by Meabco A/S, H2 2016 150

Colon Cancer – Pipeline by Medicenna Therapeutics Inc, H2 2016 151

Colon Cancer – Pipeline by Microlin Bio, Inc., H2 2016 152

Colon Cancer – Pipeline by Molecular Targeting Technologies Inc, H2 2016 153

Colon Cancer – Pipeline by MolMed SpA, H2 2016 154

Colon Cancer – Pipeline by Monopar Therapeutics LLC, H2 2016 155

Colon Cancer – Pipeline by Multimmune GmbH, H2 2016 156

Colon Cancer – Pipeline by NormOxys Inc, H2 2016 157

Colon Cancer – Pipeline by Northwest Biotherapeutics Inc, H2 2016 158

Colon Cancer – Pipeline by Novartis AG, H2 2016 159

Colon Cancer – Pipeline by Omeros Corp, H2 2016 160

Colon Cancer – Pipeline by Omnitura Therapeutics Inc, H2 2016 161

Colon Cancer – Pipeline by Oncovir Inc, H2 2016 162

Colon Cancer – Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 163

Colon Cancer – Pipeline by Orega Biotech SAS, H2 2016 164

Colon Cancer – Pipeline by OSE Immunotherapeutics, H2 2016 165

Colon Cancer – Pipeline by Panacea Pharmaceuticals Inc, H2 2016 166

Colon Cancer – Pipeline by Patrys Ltd, H2 2016 167

Colon Cancer – Pipeline by PharmaCyte Biotech Inc, H2 2016 168

Colon Cancer – Pipeline by Pharminox Ltd, H2 2016 169

Colon Cancer – Pipeline by Philogen SpA, H2 2016 170

Colon Cancer – Pipeline by Pique Therapeutics, H2 2016 171

Colon Cancer – Pipeline by Plexxikon Inc, H2 2016 172

Colon Cancer – Pipeline by ProNAi Therapeutics Inc, H2 2016 173

Colon Cancer – Pipeline by Provecs Medical GmbH, H2 2016 174

Colon Cancer – Pipeline by Provectus Biopharmaceuticals Inc, H2 2016 175

Colon Cancer – Pipeline by Qu Biologics Inc, H2 2016 176

Colon Cancer – Pipeline by Recce Pty Ltd, H2 2016 177

Colon Cancer – Pipeline by Rexahn Pharmaceuticals Inc, H2 2016 178

Colon Cancer – Pipeline by Rgenix Inc, H2 2016 179

Colon Cancer – Pipeline by Sareum Holdings Plc, H2 2016 180

Colon Cancer – Pipeline by Savoy Pharmaceuticals Inc, H2 2016 181

Colon Cancer – Pipeline by Sellas Inc, H2 2016 182

Colon Cancer – Pipeline by Sigma-Tau SpA, H2 2016 183

Colon Cancer – Pipeline by Sirnaomics Inc, H2 2016 184

Colon Cancer – Pipeline by SOM Biotech SL, H2 2016 185

Colon Cancer – Pipeline by Somantix BV, H2 2016 186

Colon Cancer – Pipeline by Sorrento Therapeutics Inc, H2 2016 187

Colon Cancer – Pipeline by Sphaera Pharma Pvt Ltd, H2 2016 188

Colon Cancer – Pipeline by Starpharma Holdings Ltd, H2 2016 189

Colon Cancer – Pipeline by Sunshine Biopharma Inc, H2 2016 190

Colon Cancer – Pipeline by Synergys Biotherapeutics Inc, H2 2016 191

Colon Cancer – Pipeline by TaiRx Inc, H2 2016 192

Colon Cancer – Pipeline by Taiwan Liposome Company Ltd, H2 2016 193

Colon Cancer – Pipeline by Takis Srl, H2 2016 194

Colon Cancer – Pipeline by Targovax ASA, H2 2016 195

Colon Cancer – Pipeline by Transgene Biotek Ltd, H2 2016 196

Colon Cancer – Pipeline by TVAX Biomedical Inc, H2 2016 197

Colon Cancer – Pipeline by Tyg Oncology Ltd, H2 2016 198

Colon Cancer – Pipeline by TyrNovo Ltd, H2 2016 199

Colon Cancer – Pipeline by Vaccinogen Inc, H2 2016 200

Colon Cancer – Pipeline by Vault Pharma Inc, H2 2016 201

Colon Cancer – Pipeline by Vaxenta Biotechnologies, H2 2016 202

Colon Cancer – Pipeline by Vaximm AG, H2 2016 203

Colon Cancer – Pipeline by VG Life Sciences Inc, H2 2016 204

Colon Cancer – Pipeline by Yakult Honsha Co Ltd, H2 2016 205

Colon Cancer – Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2016 206

Colon Cancer – Pipeline by ZIOPHARM Oncology Inc, H2 2016 207

Assessment by Monotherapy Products, H2 2016 208

Assessment by Combination Products, H2 2016 209

Number of Products by Stage and Target, H2 2016 211

Number of Products by Stage and Mechanism of Action, H2 2016 220

Number of Products by Stage and Route of Administration, H2 2016 229

Number of Products by Stage and Molecule Type, H2 2016 231

Colon Cancer – Dormant Projects, H2 2016 689

Colon Cancer – Dormant Projects (Contd..1), H2 2016 690

Colon Cancer – Dormant Projects (Contd..2), H2 2016 691

Colon Cancer – Dormant Projects (Contd..3), H2 2016 692

Colon Cancer – Dormant Projects (Contd..4), H2 2016 693

Colon Cancer – Dormant Projects (Contd..5), H2 2016 694

Colon Cancer – Dormant Projects (Contd..6), H2 2016 695

Colon Cancer – Dormant Projects (Contd..7), H2 2016 696

Colon Cancer – Dormant Projects (Contd..8), H2 2016 697

Colon Cancer – Dormant Projects (Contd..9), H2 2016 698

Colon Cancer – Dormant Projects (Contd..10), H2 2016 699

Colon Cancer – Dormant Projects (Contd..11), H2 2016 700

Colon Cancer – Dormant Projects (Contd..12), H2 2016 701

Colon Cancer – Dormant Projects (Contd..13), H2 2016 702

Colon Cancer – Dormant Projects (Contd..14), H2 2016 703

Colon Cancer – Dormant Projects (Contd..15), H2 2016 704

Colon Cancer – Dormant Projects (Contd..16), H2 2016 705

Colon Cancer – Dormant Projects (Contd..17), H2 2016 706

Colon Cancer – Dormant Projects (Contd..18), H2 2016 707

Colon Cancer – Dormant Projects (Contd..19), H2 2016 708

Colon Cancer – Discontinued Products, H2 2016 709

List of Figures

List of Figures

Number of Products under Development for Colon Cancer, H2 2016 39

Number of Products under Development for Colon Cancer – Comparative Analysis, H2 2016 40

Number of Products under Development by Companies, H2 2016 41

Number of Products under Investigation by Universities/Institutes, H2 2016 52

Comparative Analysis by Clinical Stage Development, H2 2016 56

Comparative Analysis by Early Stage Products, H2 2016 57

Assessment by Monotherapy Products, H2 2016 208

Assessment by Combination Products, H2 2016 209

Number of Products by Top 10 Targets, H2 2016 210

Number of Products by Stage and Top 10 Targets, H2 2016 210

Number of Products by Top 10 Mechanism of Actions, H2 2016 219

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 219

Number of Products by Top 10 Routes of Administration, H2 2016 228

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 228

Number of Products by Top 10 Molecule Types, H2 2016 230

Number of Products by Stage and Top 10 Molecule Types, H2 2016 230

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports